ClinicalTrials.gg
RecruitingNCT06081998Updated Nov 6, 2026

Investigation of the Effects of Sleep Deprivation on Itch and Pain Sensitivity

An interventional study of Histamine and Cowhage in Histamine, Cowhage and Sleep Deprivation, sponsored by Aalborg University. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Aalborg University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

In This experiment, the investigators would like to test following hypotheses regarding the influence of sleep deprivation on itch:

  • To investigate similarity and differences between itch and pain by comparing the effect of sleep deprivation in them.
  • To evaluate the inflammatory state induced by sleep fragmentation via the analysis of C-reactive protein (CRP) levels from blood samples.
  • To correlate the anxiety and depression scores (evaluated through questionnaires) with itch and pain sensitivity and evaluate how they are affected by sleep. In This experiment, the investigators would like to test following hypotheses regarding the influence of sleep fragmentation on itch:
  • To investigate similarity and differences between itch and pain by comparing the effect of sleep deprivation in them.
  • To evaluate the inflammatory state induced by sleep fragmentation via the analysis of C-reactive protein (CRP) levels from blood samples.
  • To correlate the anxiety and depression scores (evaluated through questionnaires) with itch and pain sensitivity and evaluate how they are affected by sleep deprivation.
Read the detailed description

Chronic itch affects approximately a fifth of the global population and is associated with substantial negative consequences for the affected individuals. Furthermore, there is a lack of efficient treatment options for chronic itch. Poor sleep is a common companion of itch and is often reported by patients with chronic itch. Poor sleep is often characterized by nightly awakenings and troubles falling asleep. This is a significant problem as poor sleep in general is associated with lowered quality of life. While previous research has already established the negative impact of itch on sleep, it is yet to be studied whether the opposite tendency might be true as well. Knowledge about patients with chronic pain has shown that poor sleep can increase the sensitivity to pain and inflammation, and this tendency can also be observed in healthy participants after experimental sleep provocations. Therefore, the investigators wish to investigate how sleep provocations affect markers of itch in healthy participants.

02

Conditions studied

  • Histamine
  • Cowhage
  • Sleep Deprivation

Browse trials for

03

In context

Sleep Deprivation

314 studies on the registry are indexed under Sleep Deprivation; 59 are open to participants now.

This study's planned enrollment of 30 is below the median of 50 across 259 interventional studies indexed under Sleep Deprivation.

Browse Sleep Deprivation studies →

Lead sponsor

Aalborg University is the lead sponsor of 183 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men and women
  • 18-60 years
  • Speak and understand English
  • Access to a smartphone during the experimental nights

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Drug addiction defined as any use of cannabis, opioids, or other drugs
  • Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses (psychiatric diagnosis) that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia etc.)
  • Moles, wounds, scars, or tattoos in the area to be treated or tested
  • Current use of medications that may affect the trial such as antihistamines and pain killers.
  • Skin diseases
  • Consumption of alcohol or painkillers 24 hours before the study days and between these
  • Acute or chronic pain and itch
  • Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)
  • Lack of ability to cooperate
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Sleep deprivation

    This subproject will be conducted in two sessions separated by three nights of sleep deprivation. Each session will last approximately 2 hours. At the beginning of the first visit and after the last visit, 9 ml of blood will be drawn, and plasma will be isolated. After plasma isolation, the CRP concentration will be analyzed. In each forearm of the participant, a 4x4 cm area will be selected as Area of Interest (AOI). In these selected areas, itch will be induced in both sessions using histamine and cowhage and several tests will be conducted.

    Other: Histamine · Other: Cowhage

Interventions

  • OtherHistamine

    Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds

  • OtherCowhage

    25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration

06

What researchers measure

Primary outcomes

  1. Assessment of itch

    Immediately following the itch provocations, participants will be instructed to rate the itch intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no itch' and 100 'worst itch imaginable'

    Time frame: Day 1: 1 minute after every itch inductions

  2. Assessment of itch

    Immediately following the itch provocations, participants will be instructed to rate the itch intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no itch' and 100 'worst itch imaginable'

    Time frame: Day 2: 1 minute after every itch inductions

  3. Assessment of pain

    Immediately following the itch provocations, participants will be instructed to rate the pain intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no pain' and 100 'worst pain imaginable'.

    Time frame: Day 1: 1 minute after every itch inductions

  4. Assessment of pain

    Immediately following the itch provocations, participants will be instructed to rate the pain intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no pain' and 100 'worst pain imaginable'.

    Time frame: Day 2: 1 minute after every itch inductions

Secondary outcomes

  1. Microvascular reactivity

    Microvascular reactivity The evoked cutaneous inflammation (quantified by superficial blood perfusion) will be measured by full-field laser perfusion imaging

    Time frame: Day 1: 10 minutes after every itch inductions

  2. Microvascular reactivity

    Microvascular reactivity The evoked cutaneous inflammation (quantified by superficial blood perfusion) will be measured by full-field laser perfusion imaging

    Time frame: Day 2: 10 minutes after every itch inductions

  3. Touch Pleasantness (TP)

    Pleasant touch sensation measured using a standardized sensory brush (SENSELab Brush-05, Somedic AB, Hörby, Sweden) exerting a force of 200 to 400 mN.The stimulation consists of three strokes (2 cm in length) over the treated/control areas. The strokes will be applied perpendicularly to the skin and the subject will rate the sensation induced by the brush on a NRS scale labeled "very unpleasant" and "very pleasant" at the extremity and "neutral" at the center.

    Time frame: Day 1: 10 minutes after every itch inductions

  4. Touch Pleasantness (TP)

    Pleasant touch sensation measured using a standardized sensory brush (SENSELab Brush-05, Somedic AB, Hörby, Sweden) exerting a force of 200 to 400 mN. The stimulation consists of three strokes (2 cm in length) over the treated/control areas. The strokes will be applied perpendicularly to the skin and the subject will rate the sensation induced by the brush on a NRS scale labeled "very unpleasant" and "very pleasant" at the extremity and "neutral" at the center.

    Time frame: Day 2: 10 minutes after every itch inductions

  5. Mechanically evoked itch (MEI), intensity approach

    MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). This stimulator is moved in intervals of 0.5 cm outside the area of itch provocation. The subjects will report a score on a NRS scale ranging 0-10.

    Time frame: Day 1: 10 minutes after every itch inductions

  6. Mechanically evoked itch (MEI), intensity approach

    MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). This stimulator is moved in intervals of 0.5 cm outside the area of itch provocation. The subjects will report a score on a NRS scale ranging 0-10.

    Time frame: Day 2: 10 minutes after every itch inductions

  7. Mechanically evoked itch, spatial approach

    The von-Frey filament that better evokes the itch sensation during the assessment of mechanically evoked itch as well as a template of soft plastic are used to map the area of hyperkinesis in the test areas (forearms). The subjects will report a score on a NRS scale ranging 0-10.

    Time frame: Day 1: 10 minutes after every itch inductions

  8. Mechanically evoked itch, spatial approach

    The von-Frey filament that better evokes the itch sensation during the assessment of mechanically evoked itch as well as a template of soft plastic are used to map the area of hyperkinesis in the test areas (forearms). The subjects will report a score on a NRS scale ranging 0-10.

    Time frame: Day 2: 10 minutes after every itch inductions

  9. Mechanical Pain Thresholds (MPT)

    This test is conducted using a pinprick set (Aalborg University, Aalborg). The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. The subjects will report a score on a NRS scale ranging 0-10.

    Time frame: Day 1: 10 minutes after every itch inductions

  10. Mechanical Pain Thresholds (MPT)

    This test is conducted using a pinprick set (Aalborg University, Aalborg). The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. The subjects will report a score on a NRS scale ranging 0-10.

    Time frame: Day 2: 10 minutes after every itch inductions

  11. Mechanical Pain Sensitivity (MPS), intensity approach

    This test is conducted with the same pinprick set used to test the MPT. Starting with the lightest, each stimulator is applied at a rate of 2 s on, 2 s off in an ascending order, and the subject will be asked to give a pain rating for each stimulus on a scale from 0-10 (where 0 indicates ''no pain'', and 10 indicates the ''worst imaginable pain'') on a NRS.

    Time frame: Day 1: 10 minutes after every itch inductions

  12. Mechanical Pain Sensitivity (MPS), intensity approach

    This test is conducted with the same pinprick set used to test the MPT. Starting with the lightest, each stimulator is applied at a rate of 2 s on, 2 s off in an ascending order, and the subject will be asked to give a pain rating for each stimulus on a scale from 0-10 (where 0 indicates ''no pain'', and 10 indicates the ''worst imaginable pain'') on a NRS.

    Time frame: Day 2: 10 minutes after every itch inductions

  13. Cold Detection Thresholds (CDT) and heat (HPT) detection

    Thermal cold and heat stimuli will be applied by a contact heat-evoked potential stimulator (PATHWAYS; Medoc Ltd, Ramat Yishai, Israel), placed 5 cm distal to the elbow on the right dorsal forearm

    Time frame: Day 1: 10 minutes after every itch inductions

  14. Cold Detection Thresholds (CDT) and heat (HPT) detection

    Thermal cold and heat stimuli will be applied by a contact heat-evoked potential stimulator (PATHWAYS; Medoc Ltd, Ramat Yishai, Israel), placed 5 cm distal to the elbow on the right dorsal forearm

    Time frame: Day 2: 10 minutes after every itch inductions

  15. Cold Detection Thresholds (CDT) and heat (HPT) pain thresholds

    Thermal cold and heat stimuli will be applied by a contact heat-evoked potential stimulator (PATHWAYS; Medoc Ltd, Ramat Yishai, Israel), placed 5 cm distal to the elbow on the right dorsal forearm

    Time frame: Day 1: 10 minutes after every itch inductions

  16. Cold Detection Thresholds (CDT) and heat (HPT) pain thresholds

    Thermal cold and heat stimuli will be applied by a contact heat-evoked potential stimulator (PATHWAYS; Medoc Ltd, Ramat Yishai, Israel), placed 5 cm distal to the elbow on the right dorsal forearm

    Time frame: Day 2: 10 minutes after every itch inductions

  17. Pain to Supra-threshold Heat Stimuli (STHS)

    The tests will be conducted by using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. The subjects will rate the pain to three suprathreshold heat pain stimuli (starting and ending at 32°C with an increase and decrease of 5°C and 3 s plateau at 50°C).

    Time frame: Day 1: 10 minutes after every itch inductions

  18. Pain to Supra-threshold Heat Stimuli (STHS)

    The tests will be conducted by using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. The subjects will rate the pain to three suprathreshold heat pain stimuli (starting and ending at 32°C with an increase and decrease of 5°C and 3 s plateau at 50°C).

    Time frame: Day 2: 10 minutes after every itch inductions

  19. Deep-tissue Pain Sensitivity Measurements

    Deep-tissue pain sensitivity will be evaluated by cuff pressure stimuli using a computer-controlled cuff algometer (Cortex Technology and Aalborg University, Denmark) including a 13-cm wide tourniquet cuff (VBM, Sulz, Germany) and an electronic visual analog scale (VAS) (Aalborg University, Denmark) for recording of the pain intensity.

    Time frame: Day 1: 10 minutes after every itch inductions

  20. Deep-tissue Pain Sensitivity Measurements

    Deep-tissue pain sensitivity will be evaluated by cuff pressure stimuli using a computer-controlled cuff algometer (Cortex Technology and Aalborg University, Denmark) including a 13-cm wide tourniquet cuff (VBM, Sulz, Germany) and an electronic visual analog scale (VAS) (Aalborg University, Denmark) for recording of the pain intensity.

    Time frame: Day 2: 10 minutes after every itch inductions

  21. Pressure Detection and Tolerance Threshold

    The pressure will be increased by 1 kPa/s and the subject will be instructed to rate the pain intensity continuously on the electronic VAS until the tolerance level is reached.

    Time frame: Day 1: 10 minutes after every itch inductions

  22. Pressure Detection and Tolerance Threshold

    The pressure will be increased by 1 kPa/s and the subject will be instructed to rate the pain intensity continuously on the electronic VAS until the tolerance level is reached.

    Time frame: Day 2: 10 minutes after every itch inductions

  23. Temporal Summation of Pain - TSP

    A total of 10 repeated mechanical pressure stimuli at the PTT level will be delivered at 0.5 Hz (1 s stimulus duration and 1 s interval between stimuli) to the lower leg. A constant pressure of 5 kPa will be applied between the individual pressure stimuli to avoid movement of the cuff. During the 10 repeated stimuli, the subject will continuously rate the pain intensity on a 10 cm continuous VAS.

    Time frame: Day 1: 10 minutes after every itch inductions

  24. Temporal Summation of Pain - TSP

    A total of 10 repeated mechanical pressure stimuli at the PTT level will be delivered at 0.5 Hz (1 s stimulus duration and 1 s interval between stimuli) to the lower leg. A constant pressure of 5 kPa will be applied between the individual pressure stimuli to avoid movement of the cuff. During the 10 repeated stimuli, the subject will continuously rate the pain intensity on a 10 cm continuous VAS.

    Time frame: Day 2: 10 minutes after every itch inductions

  25. Conditioned Pain Modulation - CPM

    The concept of CPM is that a tonic painful stimulus (conditioning stimulus) will inhibit pain evoked simultaneously from another site (test stimulus). The painful conditioned stimulus will be applied simultaneously with the assessment \- Page 4 of 6 \[DRAFT\] - stimulus. The conditioned stimulus will be terminated right after the subject presses the stop button. CPM will be defined as the difference between stimulus during and before the conditioned pain (i.e., "during" minus "before").

    Time frame: Day 1: 10 minutes after every itch inductions

  26. Conditioned Pain Modulation - CPM

    The concept of CPM is that a tonic painful stimulus (conditioning stimulus) will inhibit pain evoked simultaneously from another site (test stimulus). The painful conditioned stimulus will be applied simultaneously with the assessment \- Page 4 of 6 \[DRAFT\] - stimulus. The conditioned stimulus will be terminated right after the subject presses the stop button. CPM will be defined as the difference between stimulus during and before the conditioned pain (i.e., "during" minus "before").

    Time frame: Day 2: 10 minutes after every itch inductions

  27. The Itch Catastrophizing Scale

    The itch catastrophizing scale is a modified version of the pain catastrophizing scale (PCS), which is a validated questionnaire measuring pain-related thoughts and feelings

    Time frame: Day 1

  28. The Itch Catastrophizing Scale

    The itch catastrophizing scale is a modified version of the pain catastrophizing scale (PCS), which is a validated questionnaire measuring pain-related thoughts and feelings

    Time frame: Day 2

  29. The Pittsburg Sleep Quality Index (PSQI)

    The PSQI consists of 19 items generating seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.

    Time frame: Day 1

  30. The Pittsburg Sleep Quality Index (PSQI)

    The PSQI consists of 19 items generating seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.

    Time frame: Day 2

  31. The Hospital Anxiety and Depression Scale (HADS)

    The HADS consists of 14 items with two 7-item subscales measuring anxiety and depression symptoms, respectively

    Time frame: Day 1

  32. The Hospital Anxiety and Depression Scale (HADS)

    The HADS consists of 14 items with two 7-item subscales measuring anxiety and depression symptoms, respectively

    Time frame: Day 2

  33. Positive and Negative Affective Schedule

    This 20-item instrument is a psychometric self-report test to assess affect (10 items for positive affect and 10 items for negative affect) and validated for the use in adolescents and adults

    Time frame: Day 1

  34. Positive and Negative Affective Schedule

    This 20-item instrument is a psychometric self-report test to assess affect (10 items for positive affect and 10 items for negative affect) and validated for the use in adolescents and adults

    Time frame: Day 2

  35. Blood Sampling for C-Reactive Protein Analysis

    Whole blood samples will be collected from the antecubital vein using a vacutainer blood collection device (SMonovette, Sarstedt) with a 21-gauge needle.

    Time frame: Day 1

  36. Blood Sampling for C-Reactive Protein Analysis

    Whole blood samples will be collected from the antecubital vein using a vacutainer blood collection device (SMonovette, Sarstedt) with a 21-gauge needle.

    Time frame: Day 2

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2024, 13 months.

Of 141 non-industry interventional studies with no phase under Sleep Deprivation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 41. This study's 13 months is below that.

Counting every sponsor, half of 150 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 13, 2023
StartActual
Nov 1, 2023
Primary completionActual
Dec 30, 2024
CompletionEst.
Dec 31, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionConditioned Pain Modulation - CPM: how it is measured was reworded
  • DescriptionConditioned Pain Modulation - CPM#2: how it is measured was reworded
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionConditioned Pain Modulation - CPM: how it is measured was reworded
    • DescriptionConditioned Pain Modulation - CPM#2: how it is measured was reworded
    + 3 other changes: index terms, verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06081998
Lead sponsor
Aalborg University
Responsible party
Silvia Lo Vecchio (Assistant Professor, Aalborg University) — Principal investigator
First posted
Oct 13, 2023
Start date
Nov 1, 2023
Primary completion
Dec 30, 2024
Completion
Dec 31, 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

kristian KS Petersen
Contact
KKP@hst.aau.dk
31697510
Silvia Lo Vecchio
Contact
slv@hst.aau.dk
+4521397785

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion